Diabetic peripheral neuropathy (DPN) induces chronic neuropathic pain in diabetic patients. Current treatments like pregabalin and duloxetine offer limited efficacy. This study evaluates combining pregabalin and duloxetine versus pregabalin alone for DPN pain relief, and explores gene modulation ( and ) to understand neuropathic pain's molecular basis. Diabetic patients with DPN were randomized into groups receiving combination therapy or pregabalin alone for 4 weeks. Pain intensity, gene expression and quality of life were assessed. Combination therapy significantly reduced pain, improved quality of life and upregulated and genes compared with monotherapy. Pregabalin and duloxetine combination therapy in DPN led to mRNA upregulation and negative correlation of gene expression with pain scores. This combination therapy effectively reduced pain and improved quality of life. CTRI/2021/02/031068.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340755 | PMC |
| http://dx.doi.org/10.1080/17581869.2024.2370758 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Rheumatology (Oxford)
December 2024
Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton AB, Canada.
Objectives: To summarise and evaluate Cochrane reviews of pharmacological therapies for adults with fibromyalgia syndrome (FMS) pain.
Methods: Systematic search of Cochrane Database of Systematic Reviews to May 2024. Generic quality assessment used AMSTAR-2 criteria, validity checks of potentially critical factors in evaluation of analgesic efficacy, and assessment of susceptibility of results to publication bias.
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Rheumatology (Oxford)
December 2024
Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton AB, Canada.
Objectives: To summarise and evaluate Cochrane reviews of pharmacological therapies for adults with fibromyalgia syndrome (FMS) pain.
Methods: Systematic search of Cochrane Database of Systematic Reviews to May 2024. Generic quality assessment used AMSTAR-2 criteria, validity checks of potentially critical factors in evaluation of analgesic efficacy, and assessment of susceptibility of results to publication bias.
Comparative efficacy and safety of gabapentin, pregabalin, oxcarbazepine, and duloxetine in diabetic peripheral neuropathy: A network meta-analysis.
Perspect Clin Res
July 2024
Department of Pharmacology, Smt.NHL MMC, Ahmedabad, Gujarat, India.
Purpose: To conduct a network meta-analysis comparing the safety and efficacy of gabapentin (GBP), pregabalin (PGB), oxcarbazepine (OXC), and duloxetine (DLX) in treating diabetic peripheral neuropathy (DPN).
Materials And Methods: The study's eligibility criteria includee randomized controlled trials (RCTs) with a focus on DPN patients receiving GBP, PGB, DLX, or OXC versus placebo. Noncompliant trials with incomplete information and observational studies were excluded.
Evaluation of Effectiveness and Safety of Firstline Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population-A Randomised, Open-label, Active Comparator Study.
Ann Neurosci
May 2024
Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Background: Peripheral neuropathy is four times more common in geriatric age group patients compared to younger ones. Most of the trials have targeted adult population, and there is scarcity of data in the geriatric age group.
Purpose: A real-world study was planned on geriatric patients suffering from peripheral neuropathy to analyse the effectiveness and safety of first-line drugs used in the management of peripheral neuropathy.
Drug risks associated with sarcopenia: a real-world and GWAS study.
BMC Pharmacol Toxicol
November 2024
The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China.
Introduction: Drug-induced sarcopenia has not received adequate attention. Meanwhile, there is growing recognition of the importance of effective pharmacovigilance in evaluating the benefits and risks of medications.
Aims: The primary aim of this study is to investigate the potential association between drug use and sarcopenia through an analysis of adverse event reports from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and to evaluate the genetic factors contributing to drug-induced sarcopenia using summary-data-based Mendelian randomization (SMR).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!